Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Tekmira Pharmaceuticals Corporation (TKMR): RA Capital Management Discloses 10% Passive Stake

Page 1 of 2

It was revealed in a filing yesterday with the U.S Securities and Exchange Commission that RA Capital Management has opened a large, passive position in Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR). The filing dates back to January 12, the same day Tekmira experienced a more than 50% jump in their stock price after their announced merger with OnCore Biopharma, and shows that RA Capital has acquired 2.21 million shares of Tekmira, 9.9% of all common shares.

Peter Kolchinsky

The investment in Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) by Peter Kolchinsky’s RA Capital Management is by no means a surprise, given the hedge fund’s focus on investing in companies in the health sciences and pharmaceutical sectors, particularly those developing promising new drugs. In addition to their evidence-based investing, which is done only after rigorous studies of the product’s viability and market potential, the Boston-based fund also provides support to their portfolio companies as needed.

Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) is only the latest in a long list of health-related companies to draw the attention of RA Capital. As we reported in November, RA Capital initiated a position in Proteon Therapeutics Inc (NASDAQ:PRTO), with 8.3% of the company’s shares (1.25 million), while a month earlier they initiated a new position on TG Therapeutics Inc (NASDAQ:TGTX) with 3.14 million shares, accounting for 8.3% of TG’s common stock.

As with Tekmira, both of those recent positions are also passive by nature. While the majority of RA Capital’s holdings are passive, they do occasionally take activist positions, as in the case of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), which they’ve recently begun to heavily divest themselves of. In the third quarter alone, they sold nearly 16 million of the 24.49 million Achillion shares they owned at the start of the quarter. That selloff bumped Achillion down from the largest position in RA Capital’s equity portfolio, to third, behind Dyax Corp. (NASDAQ:DYAX) and BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). As of September 30 they had 7.81 million shares in the former, and 7.07 million shares in the latter.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!